Which mechanism is the primary action of HMG-CoA Reductase Inhibitors?

Enhance your knowledge of antihyperlipidemics and lipid management. Study with multiple choice questions and detailed explanations. Ace your test!

Multiple Choice

Which mechanism is the primary action of HMG-CoA Reductase Inhibitors?

The main idea tested is how statins work at the molecular level to lower cholesterol. HMG-CoA reductase inhibitors block the enzyme HMG-CoA reductase, which catalyzes the conversion of HMG-CoA to mevalonate—the committed, rate-limiting step in hepatic cholesterol synthesis. When hepatic cholesterol production drops, liver cells upregulate LDL receptors, pulling more LDL particles out of the bloodstream and driving down plasma LDL cholesterol. That shift in LDL clearance is the primary lipid-lowering effect of these drugs. Other options describe actions of different lipid drugs or less central effects of statins. Activating PPARα is how fibrates work to lower triglycerides and modestly raise HDL, not the main action of statins. Inhibiting intestinal cholesterol absorption is the mechanism of ezetimibe, a separate agent. Increasing HDL production is not the principal action of statins, though they may cause a small HDL rise in some patients.

The main idea tested is how statins work at the molecular level to lower cholesterol. HMG-CoA reductase inhibitors block the enzyme HMG-CoA reductase, which catalyzes the conversion of HMG-CoA to mevalonate—the committed, rate-limiting step in hepatic cholesterol synthesis. When hepatic cholesterol production drops, liver cells upregulate LDL receptors, pulling more LDL particles out of the bloodstream and driving down plasma LDL cholesterol. That shift in LDL clearance is the primary lipid-lowering effect of these drugs.

Other options describe actions of different lipid drugs or less central effects of statins. Activating PPARα is how fibrates work to lower triglycerides and modestly raise HDL, not the main action of statins. Inhibiting intestinal cholesterol absorption is the mechanism of ezetimibe, a separate agent. Increasing HDL production is not the principal action of statins, though they may cause a small HDL rise in some patients.

More practice questions